Cella S G, Locatelli V, De Gennaro V, Wehrenberg W B, Müller E E
Endocrinology. 1987 Apr;120(4):1639-43. doi: 10.1210/endo-120-4-1639.
The aim of this study was to evaluate whether in infant rats, as in adult rats, the brain adrenergic mechanisms regulate plasma GH levels and, if so, to determine the contribution of GH-releasing hormone (GHRH) and/or somatostatin (SS) pathways. In 10-day-old rats, activation of alpha 2-adrenoceptors by clonidine (CLO) was effective to stimulate GH release starting from 50 micrograms/kg ip and up to 450 micrograms/kg ip, though no dose-related effect was evident. Conversely, alpha 2-adrenoceptor blockade by yohimbine (YOH, 10 mg/kg, ip) decreased baseline GH levels. Administration of methoxamine (METHOX, 10 micrograms/rat, ip), a alpha 1-adrenoceptor agonist, significantly reduced plasma GH concentrations, while prazosin (5 mg/kg BW, ip), a specific alpha 1-adrenoceptor antagonist, stimulated plasma GH secretion. Administration of an anti-SS serum (SS-ab, 300 microliters, ip) induced a significant rise in plasma GH levels, while administration of an anti-GHRH serum (GHRH-ab, 100 microliters, ip) was associated with a striking fall in GH levels. In rats pretreated with SS-ab, administration of CLO induced a further rise in plasma GH levels. GHRH-ab significantly reduced plasma GH levels, and this effect was not altered by subsequent CLO administration. Administration of SS-ab and YOH resulted in plasma GH levels intermediate between those of rats treated with SS-ab alone or YOH alone, while pretreatment with GHRH-ab induced a lowering of plasma GH greater than when YOH was given alone. in rats pretreated with SS-ab, the GH-lowering effect of METHOX was completely lacking, while GHRH-ab and METHOX induced a lowering of plasma GH similar to that ensuing after METHOX alone or GHRH-ab alone. Administration of prazosin in rats pretreated with SS-ab did not elicit any further rise in plasma GH, while combined administration with GHRH-ab elicited a GH-lowering effect comparable to that elicited by GHRH-ab alone. These data demonstrate that in the infant rat: brain adrenergic mechanisms involved in the neural regulation of GH secretion are operative; different neuropeptide mechanisms mediate the effect of activation or inhibition of alpha 1- and alpha 2-adrenoceptors. In particular, activation of alpha 2-adrenoceptors stimulates GH secretion via endogenous GHRH release, although a mechanism operating to inhibit hypothalamic SS release cannot be excluded; stimulation of alpha 1-adrenoceptors is inhibitory to GH secretion exclusively via an increased release of hypothalamic SS.
本研究的目的是评估在幼鼠中,是否如同成年大鼠一样,脑内肾上腺素能机制调节血浆生长激素(GH)水平,若如此,则确定生长激素释放激素(GHRH)和/或生长抑素(SS)途径的作用。在10日龄大鼠中,可乐定(CLO)激活α2-肾上腺素能受体可有效刺激GH释放,腹腔注射剂量从50微克/千克起直至450微克/千克,尽管未观察到明显的剂量相关效应。相反,育亨宾(YOH,10毫克/千克,腹腔注射)阻断α2-肾上腺素能受体可降低基础GH水平。甲氧基胺(METHOX,10微克/只大鼠,腹腔注射),一种α1-肾上腺素能受体激动剂,可显著降低血浆GH浓度,而哌唑嗪(5毫克/千克体重,腹腔注射),一种特异性α1-肾上腺素能受体拮抗剂,可刺激血浆GH分泌。注射抗SS血清(SS-ab,300微升,腹腔注射)可使血浆GH水平显著升高,而注射抗GHRH血清(GHRH-ab,100微升,腹腔注射)则导致GH水平显著下降。在预先注射SS-ab的大鼠中,注射CLO可使血浆GH水平进一步升高。GHRH-ab可显著降低血浆GH水平,且随后注射CLO并未改变此效应。注射SS-ab和YOH导致的血浆GH水平介于单独注射SS-ab或YOH的大鼠之间,而预先注射GHRH-ab导致的血浆GH降低幅度大于单独注射YOH时。在预先注射SS-ab的大鼠中,完全不存在METHOX降低GH的效应,而GHRH-ab和METHOX导致的血浆GH降低与单独注射METHOX或GHRH-ab后的情况相似。在预先注射SS-ab的大鼠中注射哌唑嗪未引起血浆GH进一步升高,而与GHRH-ab联合注射时引起的GH降低效应与单独注射GHRH-ab时相当。这些数据表明,在幼鼠中:参与GH分泌神经调节的脑内肾上腺素能机制发挥作用;不同的神经肽机制介导α1-和α2-肾上腺素能受体激活或抑制的效应。特别是,α2-肾上腺素能受体的激活通过内源性GHRH释放刺激GH分泌,尽管不能排除存在抑制下丘脑SS释放的机制;α1-肾上腺素能受体的刺激仅通过下丘脑SS释放增加而抑制GH分泌。